

Emanuel Raschi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7414223/emanuel-raschi-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144
papers

2,463
citations

27
h-index

44
g-index

157
ext. papers

3,172
ext. citations

5.2
avg, IF

5.57
L-index

#	Paper	IF	Citations
144	The beta3-adrenoceptor as a therapeutic target: current perspectives. <i>Pharmacological Research</i> , 2009 , 59, 221-34	10.2	127
143	The hERG K+ channel: target and antitarget strategies in drug development. <i>Pharmacological Research</i> , 2008 , 57, 181-95	10.2	106
142	Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. <i>Pharmacology & Therapeutics</i> , 2010 , 125, 196-218	13.9	100
141	Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. <i>Drug Safety</i> , 2010 , 33, 303-14	5.1	94
140	Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 512-8	2.6	93
139	Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. <i>Cephalalgia</i> , 2015 , 35, 118-31	6.1	82
138	Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. <i>Current Medicinal Chemistry</i> , 2014 , 21, 417-36	4.3	82
137	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2013 , 50, 569-77	3.9	79
136	Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 2012 ,		58
135	hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009 , 5, 1005-21	5.5	56
134	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019 , 14, 205-221	5	54
133	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 285-93	3.8	53
132	Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. <i>Drug Safety</i> , 2013 , 36, 467-79	5.1	53
131	Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 306-14	6.1	50
130	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. <i>World Journal of Hepatology</i> , 2014 , 6, 601-12	3.4	48
129	Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. <i>BMJ, The</i> , 2016 , 353, i2231	5.9	47
128	Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. <i>Internal and Emergency Medicine</i> , 2012 , 7, 113-31	3.7	47

127	Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 894-908	3.8	46
126	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018 , 28, 533-542	4.5	45
125	Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. <i>International Journal of Cardiology</i> , 2018 , 273, 183-186	3.2	44
124	Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. <i>PLoS ONE</i> , 2013 , 8, e81208	3.7	39
123	Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. <i>Targeted Oncology</i> , 2020 , 15, 449-466	5	37
122	Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe. <i>PLoS ONE</i> , 2015 , 10, e0119551	3.7	36
121	Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. <i>World Journal of Hepatology</i> , 2015 , 7, 1761-71	3.4	33
120	Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. <i>Drug Safety</i> , 2012 , 35, 315-23	5.1	29
119	Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. <i>BMC Medicine</i> , 2014 , 12, 98	11.4	27
118	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <i>Psychotherapy and Psychosomatics</i> , 2021 , 90, 41-48	9.4	27
117	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016 , 26, 380-6	4.5	25
116	Risk-Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies. <i>Drug Safety</i> , 2016 , 39, 1175-1187	5.1	24
115	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. <i>Drug Safety</i> , 2016 , 39, 59-68	5.1	22
114	Clinically important drug-drug interactions in poly-treated elderly outpatients: a campaign to improve appropriateness in general practice. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1411-20	3.8	22
113	Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1533-1540	3.8	22
112	Drug-induced liver injury: Towards early prediction and risk stratification. <i>World Journal of Hepatology</i> , 2017 , 9, 30-37	3.4	21
111	Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis. <i>Vaccine</i> , 2018 , 36, 1548-1555	4.1	21
110	Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2018 , 132, 108-118	10.2	21

109	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 1098-1107	4.5	21
108	Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. <i>Oncologist</i> , 2019 , 24, e1228-e1231	5.7	20
107	Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. <i>Drug Safety</i> , 2015 , 38, 535-51	5.1	19
106	Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. <i>BMJ Open Diabetes Research and Care</i> , 2019 , 7, e000725	4.5	19
105	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 219-227	4.4	18
104	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2711-2723	6.7	16
103	Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1235	5.6	16
102	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. <i>Drug Safety</i> , 2018 , 41, 745-752	5.1	15
101	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1-9	3.7	15
100	Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy. <i>European Journal of Internal Medicine</i> , 2016 , 30, 31-36	3.9	15
99	Recurrence of pericarditis after influenza vaccination: a case report and review of the literature. <i>BMC Pharmacology & Toxicology</i> , 2018 , 19, 20	2.6	14
98	Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 88-98	3.8	14
97	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020 , 57, 71-80	3.9	14
96	ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. <i>EClinicalMedicine</i> , 2021 , 38, 101027	11.3	14
95	Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review. <i>European Journal of Internal Medicine</i> , 2020 , 75, 60-70	3.9	13
94	Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014 , 10, 293-305	5.5	13
93	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <i>Current Heart Failure Reports</i> , 2020 , 17, 365-383	2.8	13
92	Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis. <i>Drug Safety</i> , 2020 , 43, 1277-1285	5.1	13

91	Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	13
90	Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e120	2.4	12
89	Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. <i>International Journal of Clinical Practice</i> , 2013 , 67, 170-80	2.9	12
88	Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. <i>Frontiers in Pharmacology</i> , 2012 , 3, 198	5.6	12
87	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. <i>Drug Safety</i> , 2021 , 44, 1247-1269	5.1	12
86	Pattern of drug use among preterm neonates: results from an Italian neonatal intensive care unit. <i>Italian Journal of Pediatrics</i> , 2017 , 43, 37	3.2	11
85	Generic atypical antipsychotic drugs in Belgium: their influence and implications. <i>Journal of Comparative Effectiveness Research</i> , 2013 , 2, 551-61	2.1	11
84	Role of drugs and devices in patients at risk of sudden cardiac death. <i>Fundamental and Clinical Pharmacology</i> , 2010 , 24, 575-94	3.1	11
83	Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective. <i>Pharmacological Research</i> , 2017 , 120, 206-218	10.2	10
82	Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. <i>Polish Archives of Internal Medicine</i> , 2016 , 126, 552-61	1.9	10
81	Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1633-1640	5	10
80	Assessment of adverse reactions to lipoic acid containing dietary supplements through spontaneous reporting systems. <i>Clinical Nutrition</i> , 2021 , 40, 1176-1185	5.9	10
79	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1903-1914	4	10
78	Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 617-25	2.8	9
77	Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology. <i>World Journal of Gastroenterology</i> , 2016 , 22, 9057-9068	5.6	9
76	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. <i>Cancers</i> , 2021 , 13,	6.6	9
75	Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 233-239	2.8	9
74	Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 555-565	5.5	8

73	Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice. <i>Drug Safety</i> , 2017 , 40, 461-464	5.1	8
72	Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 558-572	2.9	8
71	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. <i>Drug Safety</i> , 2019 , 42, 1409-1422	5.1	8
70	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 869-874	4.1	8
69	Reporting of immune checkpoint inhibitor-associated myocarditis. <i>Lancet, The</i> , 2018 , 392, 383	4.0	8
68	Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320915663	3.9	8
67	DPP-4 inhibitors and venous thromboembolism: an analysis of the WHO spontaneous reporting database. <i>Lancet Diabetes and Endocrinology, the</i> , 2020 , 8, 365-367	18.1	7
66	Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling. <i>Current Drug Targets</i> , 2011 , 12, 263-86	3	7
65	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety 2019 ,		7
64	Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 199-205	5.1	7
63	Drug-induced Kounis syndrome: A matter of pharmacovigilance. <i>International Journal of Cardiology</i> , 2019 , 274, 381	3.2	6
62	Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. <i>Journal of Pharmaceutical Health Services Research</i> , 2013 , 4, 139-150	1	6
61	QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 839-41	3.8	6
60	SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system. <i>Cardiovascular Diabetology</i> , 2021 , 20, 39	8.7	6
59	Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. <i>Drug Safety</i> , 2017 , 40, 823-834	5.1	5
58	Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 715-20	2.8	5
57	Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1367-1369	4.1	5
56	Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance. <i>Drug Safety</i> , 2020 , 43, 1191-1194	5.1	5

55	ROCCA study protocol and interim analysis on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino: an observational study using active surveillance		5
54	Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase. <i>Vaccines</i> , 2021 , 9,	5.3	5
53	Advancements in drug development for diarrhea-predominant irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 251-263	5.9	4
52	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authorsPreply. <i>Internal and Emergency Medicine</i> , 2018 , 13, 635-636	3.7	4
51	Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey. <i>BMC Complementary and Alternative Medicine</i> , 2014 , 14, 262	4.7	4
50	Evolving cardiovascular uses of direct-acting oral anticoagulants: a paradigm shift on the horizon?. <i>Internal and Emergency Medicine</i> , 2017 , 12, 923-934	3.7	4
49	Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database. <i>Aging</i> , 2020 , 12, 19711-19739	5.6	4
48	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. <i>International Journal of Cancer</i> , 2021 , 149, 675-683	7.5	4
47	Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 3391-3409	4.4	4
46	Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review.. <i>JAMA Network Open</i> , 2022 , 5, e227970	10.4	4
45	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1087-1090	4	3
44	Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres. <i>PLoS ONE</i> , 2019 , 14, e0211938	3.7	3
43	Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus". <i>Clinical Pharmacokinetics</i> , 2015 , 54, 447-8	6.2	3
42	No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase. <i>Expert Review of Vaccines</i> , 2018 , 17, 363-381	5.2	3
41	Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study. <i>BMC Pharmacology & Toxicology</i> , 2019 , 20, 65	2.6	3
40	Liver injury with direct-acting anticoagulants: has the fog cleared?. <i>Heart</i> , 2017 , 103, 2010	5.1	3
39	Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 1157-1170	3.1	3
38	Reduced neuropsychiatric events as "beneficial reactions" to drugs: Seek associations with caution. <i>Brain, Behavior, and Immunity</i> , 2020 , 84, 275-276	16.6	3

37	Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. <i>Clinical Drug Investigation</i> , 2020 , 40, 1001-1008	3.3	3
36	Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 1169-1176	5.3	3
35	Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region. <i>Frontiers in Pharmacology</i> , 2020 , 11, 624888	5.6	3
34	Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1421-1431	4.1	3
33	Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies. <i>Clinical Drug Investigation</i> , 2017 , 37, 985-988	3.2	2
32	Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems. <i>Journal of Nephrology</i> , 2021 , 1	4.8	2
31	Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020 , 57, 115-116	3.9	2
30	Safety Meta-Analysis: A Call for Appropriate Use of Disproportionality Measures From Spontaneous Reporting Systems. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2193	15.1	2
29	Association between the use of proton pump inhibitors and cardiovascular events: A note of caution. <i>Neurogastroenterology and Motility</i> , 2017 , 29, e12977	4	1
28	Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e430-e431	4.6	1
27	Drug utilization research and pharmacovigilance 2016 , 399-407		1
26	Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.. <i>Targeted Oncology</i> , 2022 , 17, 43-51	5	1
25	Reply-Letter to the editor - The valuable support of spontaneous reporting systems in exploring safety profile of dietary supplements. <i>Clinical Nutrition</i> , 2020 , 39, 3854-3855	5.9	1
24	Risk of bradyarrhythmia related to ticagrelor: A systematic review and meta-analysis. <i>Pharmacological Research</i> , 2020 , 160, 105089	10.2	1
23	The safety of available treatment options for short bowel syndrome and unmet needs. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1501-1513	4.1	1
22	Stroke, Migraine and Triptans: From Bedside to Bench. <i>EBioMedicine</i> , 2016 , 6, 14-15	8.8	1
21	Switching among Equivalents in Chronic Cardiovascular Therapies: Real World Data from Italy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016 , 118, 63-9	3.1	1
20	The value of case reports and spontaneous reporting systems for pharmacovigilance and clinical practice. <i>British Journal of Dermatology</i> , 2021 , 184, 581-583	4	1

19	AuthorsPreply to Robert P. Giugliano and ColleaguesPComment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance". <i>Drug Safety</i> , 2021 , 44, 505-506	5.1	1
18	Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry. <i>Kidney International Reports</i> , 2021 , 6, 2472-2477	4.1	1
17	Impulsive conditions in ParkinsonB disease: A pharmacosurveillance-supported list. <i>Parkinsonism and Related Disorders</i> , 2021 , 90, 79-83	3.6	1
16	Glucagon-like peptide 1-based drugs and pancreatic safety. <i>JAMA Internal Medicine</i> , 2013 , 173, 1843	11.5	0
15	TELEmedicine for EPilepsy Care (TELE-EPIC): protocol of a randomised, open controlled non-inferiority clinical trial. <i>BMJ Open</i> , 2021 , 11, e053980	3	0
14	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>American Journal of Clinical Dermatology</i> , 2021 , 1	7.1	0
13	DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus. <i>Drug Safety</i> , 2020 , 43, 767-774	5.1	0
12	SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 647-650	4	0
11	Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis. <i>Mycoses</i> , 2021 , 64, 1317-1327	5.2	0
10	Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action.. <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	0
9	Development of a Network-Based Signal Detection Tool: The COVID-19 Adversome in the FDA Adverse Event Reporting System.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 740707	5.6	0
8	Reply to the Comments by Doherty et al. <i>Psychotherapy and Psychosomatics</i> , 2021 , 90, 140-141	9.4	0
7	Liver Injury with Nintedanib: A PharmacovigilanceB Pharmacokinetic Appraisal. <i>Pharmaceuticals</i> , 2022 , 15, 645	5.2	0
6	AuthorsPreply to Tufan and colleagues and Boucaud-Maitre. <i>BMJ, The</i> , 2016 , 353, i3188	5.9	
5	AuthorsPreply to Alain BraillonB Comment on "The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project". <i>Drug Safety</i> , 2016 , 39, 367-8	5.1	
4	Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.. <i>Expert Opinion on Pharmacotherapy</i> , 2022 , 1-18	4	
3	Fluoroquinolones and Aortic Disease. <i>JAMA Internal Medicine</i> , 2021 , 181, 881	11.5	
2	Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market. <i>European Psychiatry</i> , 2021 , 64, S150-S151	6	

- 1 Letter to the editor: RECAM for the diagnosis of DILI-Is it time to incorporate additional pharmacological criteria?. *Hepatology*, **2022**,

11.2